Erectile Dysfunction Treatment Options: How the Choice Is Made

No single erectile dysfunction (ED) treatment is appropriate for every man. Current guidance favours personalised decision-making rather than forcing everyone through an identical sequence. The choice depends on the likely cause of ED, cardiovascular and general health, medicine interactions, erectile severity, previous treatment experience, invasiveness, side effects, practicality and patient preference. In many men, risk-factor management and PDE5-inhibitor medicines are considered early; other options include vacuum devices, injection therapy, selected shockwave therapy, psychological interventions and penile prosthesis surgery.

Why do ED treatment options differ between patients?

Two men can have the same symptom but very different clinical problems. One may have mild vasculogenic ED associated with smoking and hypertension; another may have severe neurogenic ED after pelvic surgery. A third may have adequate spontaneous erections but situational performance anxiety.

That is why treatment selection should answer several questions first:

• What is the most likely mechanism?
• Are there reversible or modifiable contributors?
• Is sexual activity medically safe in the current cardiovascular context?
• Are there medicines that make a proposed ED drug unsafe?
• What has already been tried, and was it used correctly?
• How invasive a treatment is acceptable to the patient?
• Does the patient want an on-demand, non-drug, minimally invasive or surgically definitive option?

What are the main treatment categories?

Depending on the clinical situation, ED management can include:

• lifestyle and cardiovascular/metabolic risk-factor management;
• review of medicines that may affect sexual function;
• PDE5 inhibitors;
• vacuum erection devices;
• intracavernosal injections;
• topical or intraurethral alprostadil where available;
• psychological or psychosexual interventions;
• testosterone treatment only for appropriately diagnosed androgen deficiency;
• low-intensity shockwave therapy in selected vasculogenic ED;
• penile prosthesis surgery.

These are not interchangeable. Some improve erectile response only while being used; some address a contributory health problem; a penile implant provides mechanical rigidity through surgery.

What role do lifestyle and general health measures play?

They should usually be addressed before or alongside ED-specific treatment. Smoking, low physical activity, obesity, hypertension, abnormal lipids and diabetes are relevant because erectile and cardiovascular health overlap.

Lifestyle change is not a substitute for treating severe ED and does not reliably resolve the condition on its own. Its role is to modify risk where possible and improve the wider health context in which ED occurs.

Should prescribed medicines be stopped if they may affect erections?

No. Some antihypertensives, antidepressants, antipsychotics and other medicines can contribute to sexual dysfunction, but stopping treatment abruptly may be unsafe. A clinician can review the timing, indication, alternatives and other possible causes before any change is made.

When are oral ED medicines considered?

PDE5 inhibitors such as sildenafil, tadalafil, vardenafil and avanafil are first-line medical therapy for many men with ED. They enhance the natural erectile response to sexual stimulation; they do not trigger an erection in the absence of arousal and they do not automatically correct the underlying disease.

Choice among agents can take into account duration of action, timing, food effects, side effects, other medicines and the patient’s pattern of sexual activity.

Who needs particular caution with PDE5 inhibitors?

The most important contraindication is concurrent use of organic nitrates or nitric-oxide donors. The combination can cause a dangerous fall in blood pressure. Riociguat is also incompatible with sildenafil and related PDE5-inhibitor therapy.

Men with unstable or high-risk cardiovascular disease may need assessment before resuming sexual activity or starting ED medication. A medication history should therefore be part of prescribing, not an afterthought.

What if the first tablet does not work?

One unsuccessful attempt is not enough to define treatment failure. Common reasons for apparent non-response include incorrect timing, insufficient sexual stimulation, food delaying absorption for some drugs, use of an unregulated product, or inadequate counselling about how the medicine works.

The next step may be optimisation, a different PDE5 inhibitor in selected circumstances, assessment for testosterone deficiency where clinically indicated, or discussion of another treatment class. It should not be unsupervised dose escalation.

Are herbal or “natural male enhancement” products a reasonable substitute?

They should not be assumed to be safer simply because they are labelled natural. Supplements may have limited evidence, variable composition and potential interactions. Regulators have repeatedly identified sexual-enhancement products containing undeclared prescription-drug ingredients.

Current EAU guidance notes only mild potential benefit from some supplements in selected mild ED and gives a weak recommendation in men who refuse pharmacological treatment after counselling. That is not equivalent to evidence supporting commercial “male enhancement” mixtures.

How do vacuum erection devices work?

A vacuum erection device (VED) creates negative pressure around the penis to draw blood into the erectile tissue. A constriction ring can then help maintain rigidity.

VEDs are drug-free and non-invasive, which can make them useful when medication is unsuitable or unwanted. Drawbacks can include discomfort, bruising, numbness and interference with ejaculation. In medical VED use, the constriction ring should not remain in place for prolonged periods; EAU guidance notes removal within 30 minutes to reduce the risk of serious skin injury.

VEDs require practical instruction and should be selected carefully in men with bleeding disorders or relevant anticoagulant use.

When are penile injections considered?

Intracavernosal injection therapy delivers a vasoactive medicine directly into the erectile tissue. Alprostadil is an established option, and injections can be considered at different stages of personalised ED care, including when tablets are unsuitable or ineffective.

Treatment requires in-person instruction because dose selection, injection technique, prolonged erection and priapism risk matter. The medicine should not be self-selected from internet dosing guides.

Is intraurethral treatment the same as an injection?

No. Alprostadil can also be delivered through certain topical or intraurethral formulations in some countries. These are different routes, with different efficacy, adverse effects and availability. They should not be grouped together simply because both avoid oral tablets.

When does testosterone treatment help?

Testosterone is not a general ED drug. It may be appropriate when a man has symptoms of androgen deficiency and biochemical testing supports the diagnosis, after contraindications and monitoring needs are reviewed.

Using testosterone in a man with normal androgen status does not follow from the diagnosis of ED alone.

When is psychological or relationship-focused treatment relevant?

When anxiety, depression, relationship distress, negative sexual expectations or performance monitoring contribute to ED, psychological intervention can be clinically important. EAU guidance supports cognitive-behavioural approaches, including partner involvement where appropriate, and notes that combining psychological and medical treatment can improve outcomes in suitable patients.

The presence of an organic cause does not rule out psychological support, and the presence of anxiety does not rule out medical assessment.

Where does low-intensity shockwave therapy fit?

Low-intensity shockwave therapy is a selected option for vasculogenic ED, not a generic “erection booster”. Current EAU recommendations are weak because the average benefit is modest and studies vary in device type, energy, session schedule and patient selection.

Potential candidates include selected men with mild vascular-pattern ED, as well as some patients whose response to PDE5 inhibitors remains inadequate. Men with advanced neurological injury or severe end-stage erectile tissue damage should not be told that shockwave therapy is an equivalent substitute for a penile implant.

See shockwave therapy for erectile dysfunction.

What about PRP, P-Shot, stem cells and exosomes?

These approaches are often presented commercially as “regenerative”. Evidence remains less mature than for established therapies. Current EAU guidance states that available PRP evidence is insufficient for a treatment recommendation. Stem-cell and exosome interventions also require better-quality clinical evidence before they can be treated as routine standards of care.

The correct counselling is therefore about uncertainty, not a promise of restoration or tissue “regeneration”.

When is a penile prosthesis considered?

A penile prosthesis can be considered when other treatments fail, cannot be used, are unacceptable to the patient, or when an informed patient prefers a definitive mechanical solution after counselling.

The implant is surgically placed inside the penis. Inflatable and malleable systems exist. The choice involves infection and mechanical risks, long-term device considerations, the patient’s manual dexterity and a clear understanding that the operation changes the erectile tissue permanently.

A prosthesis provides rigidity; it does not directly increase libido, determine whether orgasm occurs, restore ejaculation after prostate surgery or function as a cosmetic lengthening procedure.

For device mechanics and surgical implications, see penile prosthesis. The separate when to consider a penile implant page focuses on decision criteria.

Can treatment options be combined?

Sometimes. Combination strategies may be useful when one treatment gives an incomplete response, but the evidence is not equally strong for every combination. Examples discussed in contemporary guidance include PDE5 inhibitors with selected devices or low-intensity shockwave therapy in particular circumstances.

Combination treatment should have a clinical rationale. “More treatments at once” is not itself a strategy, and combining vasoactive medicines without supervision can be unsafe.

How is the most suitable option selected?

Medical and sexual history

The pattern and severity of ED, associated desire or ejaculation problems, cardiovascular risk, prior surgery, medicines, psychological factors and previous treatment experience are reviewed.

Physical examination

Blood pressure, metabolic clues, endocrine or neurological signs and genital findings can change both diagnosis and treatment choice.

Basic laboratory testing

Glucose/HbA1c, lipids and early-morning total testosterone are part of the basic work-up when current results are not available. Other tests are targeted to the clinical question.

Advanced testing

Penile duplex ultrasound or nocturnal erection testing is reserved for selected patients. Testing should alter decision-making rather than become a routine package.

Shared decision-making

Effectiveness matters, but so do invasiveness, side effects, spontaneity, cost, partner context, manual dexterity, acceptability and the patient’s priorities. A technically effective option that the patient will not use is not a useful treatment plan.

When should treatment be reassessed?

Reassessment is appropriate when:

• response is inadequate despite correct use;
• adverse effects are unacceptable;
• the pattern of ED changes;
• new cardiovascular, endocrine or neurological symptoms appear;
• the patient is considering a more invasive option;
• treatment is discontinued because it does not fit the person’s expectations or lifestyle.

Follow-up should assess more than erection hardness. Safety, satisfaction, sexual function and whether the original diagnosis still fits all matter.

Medical information note

This page compares treatment pathways rather than prescribing a treatment. Individual medicine choice, dose, injection technique and surgical suitability require medical assessment.